Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) EBIT: 2023-2025

Historic EBIT for Upstream Bio (UPB) over the last 2 years, with Sep 2025 value amounting to -$37.8 million.

  • Upstream Bio's EBIT fell 100.25% to -$37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.5 million, marking a year-over-year decrease of 113.62%. This contributed to the annual value of -$77.8 million for FY2024, which is 93.86% down from last year.
  • Per Upstream Bio's latest filing, its EBIT stood at -$37.8 million for Q3 2025, which was up 14.69% from -$44.3 million recorded in Q2 2025.
  • In the past 5 years, Upstream Bio's EBIT ranged from a high of -$9.4 million in Q3 2023 and a low of -$44.3 million during Q2 2025.
  • For the 3-year period, Upstream Bio's EBIT averaged around -$24.0 million, with its median value being -$18.9 million (2024).
  • Data for Upstream Bio's EBIT shows a maximum YoY slumped of 152.83% (in 2025) over the last 5 years.
  • Upstream Bio's EBIT (Quarterly) stood at -$14.3 million in 2023, then plummeted by 83.66% to -$26.3 million in 2024, then crashed by 100.25% to -$37.8 million in 2025.
  • Its last three reported values are -$37.8 million in Q3 2025, -$44.3 million for Q2 2025, and -$32.0 million during Q1 2025.